Koen Bezemer
General Manager Erasmus MC
General Manager leading development of innovative pharmaceuticals in the field of Tumor Immunology. Our research mainly focusses on Mesothelioma and Pancreatic Cancer. The aim is to maximise clinical efficacy of our Dendritic Cell Therapy & Neoantigen Cancer Vaccines and advance them further into the clinic. Trained as a biologist, I have over 15 years of experience in the field of Cell and Gene therapy. Over the past four years, my work has expanded into the neoantigen field, bridging advanced immunotherapy approaches with personalized cancer vaccine development.
Seminars
While cancer vaccines and T-cell therapies have demonstrated encouraging progress in targeting neoantigens, significant challenges remain in optimising tumour specificity, overcoming immune evasion, and improving clinical response rates. To overcome this, there is growing interest in expanding beyond traditional platforms to include alternative modalities such as bispecific antibodies, ADCs, targeted small molecules and other next-generation biologics. This workshop will provide a comprehensive and comparative evaluation of emerging neoantigen targeting strategies to help you select the most appropriate modality for your programme.
This workshop will gather experts to discuss:
- Review the latest advancements in cancer vaccines and T-cell therapies to understand their advantages
- Explore what the emerging technologies are and the advantages of each
- Compare all the modalities against each other to understand their mechanism of action and how that helps improve tumour targeting
- Strategically choose which therapeutic is the most appropriate for the tumour type and your clinical objectives
- Discuss the drawbacks of novel modalities in targeting neoantigens to gain a holistic overview
